PROCC: a predictive score to identify KRAS wild type metastatic colorectal cancer patients who are likely to obtain survival benefit from panitumumab treatment

Background Practice guidelines recommend using panitumumab in combination with chemotherapy to treat KRAS wild-type (WT) metastatic colorectal cancer (mCRC) patients where it was shown to significantly extend progression-free survival (PFS) and overall survival (OS). Still, a proportion of patients will not achieve this goal. We propose a simplified predictive score to identify patients who are…